Wang L, Tang J, Wang L, et al
No comprehensive drug interaction studies exist for IV glutathione
A responsible provider should discuss your medical history, current medications, allergy status, baseline B12 levels, the specific form of B12 being administered, and the expected benefits and risks before proceeding with an injection
The metabolism and elimination of NAD+ (and its by-products) could be altered in advanced hepatic or renal dysfunction, and high-dose NAD+ might theoretically affect cardiovascular dynamics, so practitioners generally avoid or closely supervise NAD+ use in such settings
For the FIB-4 threshold of 2, regardless of age which concerned 33% of the FIB-4 positive subjects (n=284), 74% of the FIB-4 2 subjects were confirmed by ELF testing versus 51% of those with a FIB-4 score 5000 patients that were screened in the RESOLVE-IT Phase 3 trial (NCT02704403), those with non-historical LB, NIS2+ and FIB-4 available, and 90 days between LB and serum sample collection were selected, resulting in a cohort of 1929 patients